Canaan IX L.P.

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
29
Insider Sells Sum
$13.86M

Insider Activity of Canaan IX L.P.

The largest sale of all time was on 2016-06-06 and amounted to 203534 shares of CytomX Therapeutics, Inc. for $2.04M.

Biography of Canaan IX L.P.

No biography is available at this moment.

2016-11-29SaleCytomX Therapeutics, Inc.
CTMX
director
44,172
0.1228%
$11.18$494,015+33.83%
2016-11-28SaleCytomX Therapeutics, Inc.
CTMX
41,680
0.1155%
$11.33$472,284+31.38%
2016-11-25SaleCytomX Therapeutics, Inc.
CTMX
13,458
0.0371%
$11.79$158,682+25.32%
2016-11-23SaleCytomX Therapeutics, Inc.
CTMX
21,780
0.0592%
$11.84$257,843+22.86%
2016-11-22SaleCytomX Therapeutics, Inc.
CTMX
85,100
0.236%
$11.71$996,155+26.82%
2016-11-21SaleCytomX Therapeutics, Inc.
CTMX
27,096
0.0741%
$11.72$317,571+24.85%
2016-11-18SaleCytomX Therapeutics, Inc.
CTMX
25,610
0.0702%
$11.64$298,170+25.94%
2016-11-17SaleCytomX Therapeutics, Inc.
CTMX
37,942
0.1046%
$11.50$436,435+27.98%
2016-11-16SaleCytomX Therapeutics, Inc.
CTMX
37,034
0.1046%
$11.55$427,906+30.12%
2016-11-15SaleCytomX Therapeutics, Inc.
CTMX
66,128
0.1825%
$11.48$758,951+27.83%
2016-11-14SaleCytomX Therapeutics, Inc.
CTMX
47,488
0.1298%
$11.21$532,113+29.58%
2016-11-11SaleCytomX Therapeutics, Inc.
CTMX
70,782
0.1952%
$11.20$792,921+30.6%
2016-11-10SaleCytomX Therapeutics, Inc.
CTMX
54,270
0.1509%
$11.07$600,780+33.12%
2016-11-09SaleCytomX Therapeutics, Inc.
CTMX
27,460
0.076%
$11.03$302,996+32.86%
2016-06-10SaleCytomX Therapeutics, Inc.
CTMX
5,400
0.0147%
$10.01$54,054+16.13%
2016-06-09SaleCytomX Therapeutics, Inc.
CTMX
45,684
0.1268%
$10.06$459,581+17.63%
2016-06-08SaleCytomX Therapeutics, Inc.
CTMX
45,770
0.1257%
$10.08$461,362+15.9%
2016-06-07SaleCytomX Therapeutics, Inc.
CTMX
19,462
0.0541%
$10.03$195,204+17.52%
2016-06-06SaleCytomX Therapeutics, Inc.
CTMX
203,534
0.5642%
$10.01$2.04M+17.35%
2016-06-03SaleCytomX Therapeutics, Inc.
CTMX
36,856
0.1019%
$10.83$399,150+8.02%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.